Samsung Biologics signs largest CMO deal…KRW 2 Trillion

First big deal of the year, 40% of the total order value of the previous year

Largest order ever renewed in 3 months, expands global market presence

Pic of Samsung Biologics (Source: Samsung Biologics)

Samsung Biologics announced on the 14th that it has signed a contract manufacturing organization (CMO) agreement worth USD 1.41 billion (approximately KRW 2.74 trillion) with a Europe-based pharmaceutical company.

 

This is the largest contract in Samsung Biologics' history.

 

It represents 40% of the total order value of KRW 5.4035 trillion last year.

 

The contract will run through December 31, 2030.

 

The customer and product names were not disclosed due to confidentiality.

 

With the contract, Samsung Biologics has broken its record for the largest order.

 

The record renewal comes just 3 months after the company signed a contract worth KRW 1.7028 trillion with an Asian pharmaceutical company in October last year.

 

Last year, Samsung Biologics further solidified its position in the global market by signing 3 “big deals” worth KRW 1 trillion in major markets including the U.S., Europe, and Asia.

 

Last year's annual orders totaled at KRW 5.4035 trillion, the largest ever amount, a 1.5 times increase compared to the previous year.

 

Samsung Biologics currently has 17 of the top 20 global pharmaceutical companies as customers.

 

Based on its core order-winning competitiveness, including overwhelming production capacity, quality competitiveness, and multiple track records, the company's cumulative order total has exceeded USD 17.6 billion since its establishment.

 

Samsung Biologics is expanding its production capacity to proactively prepare for the growing demand for biopharmaceuticals.

 

Plant 5, a 180,000-liter production plant that will incorporate the best practices of Plants 1 through 4, is under construction and is scheduled to be operational in April.

 

Upon completion, Samsung Biologics will have a total production capacity of 784,000L.

 

In terms of quality, Samsung Biologics has proven its competitiveness in all stages of drug manufacturing and management, including a 99% batch success rate.

 

As of December 2024, the company has obtained a total of 340 global regulatory approvals, including 41 from the U.S.

 

Food and Drug Administration (FDA) and 36 from the European Medicines Agency (EMA).

 

Its regulatory on-site inspection pass rate is also among the highest in the industry.

 

Samsung Biologics has been participating in a series of large-scale pharmaceutical and biotech industry conferences in the U.S., Europe, and Asia to strengthen business networking and order acquisition activities.

 

Samsung Biologics is participating in the '2025 JP Morgan Healthcare Conference', the largest investment event in the pharmaceutical and biotechnology industry that is being held in San Francisco, U.S.A., from April 13-16 to strengthen networking for business expansion.